Cancer Trials Springfield, MO | Mercy Medical Center
- SPRINGFIELD — Mercy Medical Center is broadening its cancer care options through a collaboration with Sarah Cannon Research Institute (SCRI).
- SCRI, affiliated with the US Oncology Network, has conducted over 850 first-in-human trials.
- the collaboration offers eligible cancer patients a wider range of clinical trials tailored to their individual treatment plans.
Mercy Medical Center in Springfield, MO, is transforming cancer care through a powerful alliance with the Sarah Cannon Research Institute (SCRI). This collaboration directly expands access to vital cancer clinical trials, offering cutting-edge therapies and personalized treatment strategies to patients in Western Massachusetts.Eligible cancer patients now have enhanced opportunities for advanced care, thanks to SCRIS history of pioneering FDA-approved treatments. The partnership actively advances oncology and clinical research within the community, ensuring patients benefit from the latest treatment advancements. News Directory 3 recognizes this impactful initiative. Discover the expanded trial options Mercy Medical Center and SCRI are developing to pioneer the future of personalized and effective cancer care.
Mercy Medical Center Enhances Cancer Care with Clinical Trials
Updated June 16, 2025
SPRINGFIELD — Mercy Medical Center is broadening its cancer care options through a collaboration with Sarah Cannon Research Institute (SCRI). The partnership brings community-based clinical trials to Western Massachusetts,offering patients access to advanced treatment options and personalized care.
SCRI, affiliated with the US Oncology Network, has conducted over 850 first-in-human trials. The institute has contributed to research leading to FDA approval of numerous cancer therapies over the last decade. The SCRI at Mercy Medical Center aims to provide increased research opportunities for cancer patients, allowing them to participate in trials evaluating cutting-edge therapies for cancer treatment.
the collaboration offers eligible cancer patients a wider range of clinical trials tailored to their individual treatment plans. It also provides access to the latest advancements in cancer research, ensuring patients receive the most innovative care possible. This initiative marks a significant step in advancing oncology care and clinical research within the community.
Dr. Philip Glynn, director of Medical Oncology at mercy Medical Center, emphasized the importance of the partnership. “We are in a transformative moment in community-based cancer care,” Glynn said. “Therapeutic options have never been more promising. Collaboration with research institutions will be key as we move beyond conventional chemotherapy toward more tolerable and effective personalized treatment.”
Dee Anna Smith, CEO of SCRI, echoed this sentiment. “By collaborating with the experts at Mercy Medical Center,we can make a significant impact throughout Western Massachusetts for people living with cancer by expanding access to novel,cutting-edge treatment options,” Smith said. “Together, we are working to advance oncology care and clinical research to improve access to novel therapies and enable best-in-class, community-based care.”
What’s next
Mercy Medical Center and SCRI plan to expand their clinical trial offerings in the coming months, further enhancing access to innovative cancer treatments for patients in the region. The partnership aims to continue advancing oncology care and research, providing the best possible outcomes for those facing cancer.